Navigation Links
New Mask Study Supports CDC's Updated Guidance for Seasonal Flu Prevention Strategies

HAUPPAUGE, N.Y., Sept. 29 /PRNewswire/ -- Crosstex International, a subsidiary of Cantel Medical Corp. (NYSE: CMN), announced today the publication of sponsored research that suggests a far greater infection prevention value of medical face masks, commonly referred to as surgical masks, than previously understood. The key outcome challenges conventional wisdom that a medical mask or respirator is most effective when worn by a person attempting to protect oneself from exposure to infectious matter.  Instead, if FDA-cleared medical face masks are worn at the potential source of the infection, the level of overall protection is magnified up to 300-fold.  Published in the September issue of the American Journal of Infection Control, the research study, entitled "Quantifying Exposure Risk and Mask Protection", was conducted by Keith Diaz, MD, and Gerald Smaldone, MD, PhD, at Stony Brook University Medical Center in Stony Brook, NY.

This study supports the newest Centers for Disease Control and Prevention guidelines (September 2010) on Seasonal Influenza Prevention Strategies in Healthcare Settings, which recommend the use of medical face masks to minimize potential exposure to influenza viruses in healthcare settings.  The simulated bench study examined the efficacy of N95 respirators and medical face masks in their ability to reduce exposure to infectious particles when used either as protective devices (to protect the wearer) or as "source control" devices (to control infection at the source, such as a person with flu-like symptoms).  The authors' results demonstrate "the most important factor in reducing exposure was deflection of exhaled particles at the source."  

"This evidence offers healthcare providers and public health officials new insight into the benefit of medical face masks as source control devices," said Gary Steinberg, CEO of Crosstex International.  "It was clear that medical face masks were being narrowly compared to N95 respirators for their ability to protect the wearer from the outside-in.  We wanted to better understand the value of medical face masks for source control, that is, protecting others from the inside-out," said Matt Conlon, Vice President at Cantel Medical.  While medical face masks are commonly referred to as "PPE" (Personal Protection Equipment), their original purpose was to protect the patient from acquiring an infection from the physician.  This new research is the first to quantify their important role in controlling the infection at the source and further demonstrated that a tighter fitting medical mask performs best in source control.  

The findings come in the wake of the 2009 H1N1 pandemic when there were significant complications, shortages, and debate surrounding the CDC's formal recommendation for the use of N95's by healthcare workers for protection against the H1N1 virus. Steinberg said, "This shows an exponential infection control benefit at a fraction of the cost and complexity of using N95 respirators.  As one of the few remaining U.S. manufacturers of medical masks, it is important for Crosstex to continue funding this type of independent research to address infectious disease threats through continued mask innovation. We don't overlook the fact that masks are medical devices.  We understand they can save lives and dramatically reduce costs associated with respiratory-borne infections."

About Crosstex International, Inc.

A division of Cantel Medical Corp., Crosstex manufactures a wide array of infection prevention and control products for the healthcare industry.  Founded in 1953 and headquartered in Hauppauge, New York, Crosstex sells branded and private label products including face masks, which are 100% manufactured in its FDA-registered New York facility.  Sold in more than 100 countries, Crosstex products include sterilization pouches and accessories, patient towels and bibs, eyewear, surface disinfectants and deodorizers, germicidal wipes, hand sanitizers, gloves, sponges, cotton products, needles and syringes, scalpels and blades, sharps containers, saliva ejectors and evacuator tips.  For further information, visit the Crosstex website at

About Cantel Medical Corp.

Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.  For further information, visit the Cantel Medical website at

SOURCE Crosstex International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010
2. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
3. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
4. Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
5. Independent Community Pharmacies Earn High Customer Satisfaction Scores in Latest J.D. Power and Associates National Pharmacy Study
6. 12-Month Study Reports Efficacy Rates for AMS Elevate Apical and Posterior Prolapse Repair System
7. Facelift Healing Innovation: New Study Shows Hyperbaric Oxygen Therapy Decreases Bruising in Facelifts Patients by 35%
8. Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine
11. Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges
Post Your Comments:
(Date:11/24/2015)... 2015 Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide, announced ... will present at the 27 th Annual Piper ... 11:30 a.m. ET. The conference will be held at ... York City . Abaxis, Inc. is ...
(Date:11/24/2015)... , Nov. 24, 2015  Eyewear brand Revo ... with U2 lead singer and activist Bono as part of ... vision impairment and blindness in more than 5 million people ... Revo will donate $10 from the sale of every pair ... to a total of $10 million to the "Buy Vision, ...
(Date:11/24/2015)... , Nov. 24, 2015   Mast Therapeutics, Inc. ... its molecular adhesion and sealant technology (MAST) platform to ... and stroke, today announced that the Company,s Chief Executive ... the Piper Jaffray 27 th Annual Healthcare Conference ... at the New York Palace hotel in ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five seconds to ... that the first impression be positive and reflects business values. If a client starts ... or want to return. They will also share their thoughts about a business with ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron Foley ... to yield insights into how to detect and treat pancreatic cancer (PC). , ... small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood of ...
(Date:11/24/2015)... ... 24, 2015 , ... Sir Grout of Baltimore is proud ... The award recognizes good companies for excellence in service and a commitment to ... hard surface restoration company earned this recognition after a thorough review by the ...
Breaking Medicine News(10 mins):